Clinical Trials Browser

Phase 1/2 × Completed × eribulin × Clear all

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT01126736 2023-06-22

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Phase 1/2 Completed

98 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03245450 2022-06-28

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Phase 1/2 Completed

40 enrolled 30 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT02513472 2022-05-05

ENHANCE-1

Phase 1/2 Completed

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01554371 2021-02-03

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Phase 1/2 Completed

44 enrolled 14 charts

Breast Neoplasms, Carcinoma

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

Phase 1/2 Completed

76 enrolled 24 charts

Breast Neoplasms

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

67 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02723877 2019-03-22

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Phase 1/2 Completed

Breast Neoplasms